Sarepta Therapeutics, Inc. $SRPT Shares Sold by AXQ Capital LP

Key Points

• AXQ Capital LP cut its Sarepta Therapeutics stake by 51.2% in the second quarter, selling 50,238 shares and retaining 47,974 shares valued at approximately $862,000.
• Institutional investors own 86.68% of SRPT, while the stock recently traded at $22.50, within a 52-week range of $14.68 to $25.32.
• Sarepta exceeded quarterly earnings and revenue estimates, but revenue fell 34.3% year over year. Analysts maintain a consensus “Hold” rating with an average price target of $25.06.

AXQ Capital LP trimmed its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 51.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 47,974 shares of the biotechnology company's stock after selling 50,238 shares during the period. AXQ Capital LP's holdings in Sarepta Therapeutics were worth $862,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the business. PNC Financial Services Group Inc. lifted its holdings in shares of Sarepta Therapeutics by 7.8% in the 1st quarter. PNC Financial Services Group Inc. now owns 8,751 shares of the biotechnology company's stock valued at $190,000 after buying an additional 636 shares during the period. Thrivent Financial for Lutherans grew its stake in shares of Sarepta Therapeutics by 3.3% during the 2nd quarter. Thrivent Financial for Lutherans now owns 23,140 shares of the biotechnology company's stock worth $396,000 after purchasing an additional 744 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Sarepta Therapeutics by 1.8% during the 3rd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,208 shares of the biotechnology company's stock valued at $829,000 after purchasing an additional 758 shares in the last quarter. Larson Financial Group LLC boosted its holdings in Sarepta Therapeutics by 82.5% during the fourth quarter. Larson Financial Group LLC now owns 1,882 shares of the biotechnology company's stock worth $41,000 after buying an additional 851 shares in the last quarter. Finally, Public Employees Retirement System of Ohio boosted its holdings in Sarepta Therapeutics by 3.1% during the first quarter. Public Employees Retirement System of Ohio now owns 28,787 shares of the biotechnology company's stock worth $626,000 after buying an additional 875 shares in the last quarter. 86.68% of the stock is owned by hedge funds and other institutional investors.

Sarepta Therapeutics Price Performance

SRPT stock opened at $22.50 on Friday. Sarepta Therapeutics, Inc. has a 1 year low of $14.68 and a 1 year high of $25.32. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.42 and a quick ratio of 2.62. The firm has a market capitalization of $2.38 billion, a PE ratio of -7.76, a price-to-earnings-growth ratio of 0.32 and a beta of 0.27. The business has a 50 day simple moving average of $18.26 and a 200-day simple moving average of $18.47.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.64 EPS for the quarter, topping analysts' consensus estimates of $0.22 by $0.42. Sarepta Therapeutics had a negative return on equity of 1.60% and a negative net margin of 13.48%.The firm had revenue of $401.25 million for the quarter, compared to the consensus estimate of $366.39 million. During the same quarter last year, the business posted $2.02 earnings per share. The firm's revenue was down 34.3% compared to the same quarter last year. Equities research analysts anticipate that Sarepta Therapeutics, Inc. will post 3.52 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on SRPT. Piper Sandler reduced their price target on Sarepta Therapeutics from $23.00 to $20.00 and set a "neutral" rating for the company in a report on Thursday, July 9th. Weiss Ratings downgraded Sarepta Therapeutics from a "sell (d)" rating to a "sell (e+)" rating in a research note on Wednesday, August 19th. Wall Street Zen cut shares of Sarepta Therapeutics from a "buy" rating to a "hold" rating in a research note on Saturday, August 8th. HC Wainwright restated a "buy" rating on shares of Sarepta Therapeutics in a research report on Tuesday, July 28th. Finally, Wolfe Research raised shares of Sarepta Therapeutics from a "peer perform" rating to an "outperform" rating and set a $27.00 price objective on the stock in a report on Thursday, July 9th. Nine equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and five have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $25.06.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta's core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company's mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta's commercial products include several exon-skipping therapies approved by the U.S.

Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source